Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure.

IF 3.1 Q2 PERIPHERAL VASCULAR DISEASE

High Blood Pressure & Cardiovascular Prevention Pub Date : 2024-08-22 DOI:10.1007/s40292-024-00664-y

Yabing Cao, Yunjing Sun, Bo Miao, Xiao Zhang, Qingzhou Zhao, Liping Qi, Yaoqi Chen, Lingling Zhu

{"title":"Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure.","authors":"Yabing Cao, Yunjing Sun, Bo Miao, Xiao Zhang, Qingzhou Zhao, Liping Qi, Yaoqi Chen, Lingling Zhu","doi":"10.1007/s40292-024-00664-y","DOIUrl":null,"url":null,"abstract":"Introduction: Hypertensive heart failure (HHF) has a high incidence and poor prognosis.Aim: This article evaluated the efficacy and safety of Vericiguat in HHF and analyzed the relationship between C-reactive protein (CRP) levels and patient prognosis.Methods: 110 HHF patients were divided into Placebo and Vericiguat groups. Cardiac function was assessed by echocardiography and 6-minute walk test (6MWT). Blood samples were collected to detect the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI), endothelin (ET-1), nitric oxide (NO), and CRP.Results: Left ventricular end systolic diameter (LVESD) and left ventricular end diastolic dimension (LVEDD) were reduced, the left ventricular ejection fraction (LVEF) and 6MWT were increased, and the serum levels of NT-proBNP, cTnI, ET-1, NO, and CRP were decreased in Vericiguat group as against Placebo group; The total effective rate was 76.4% in Placebo group and 92.7% in Vericiguat group (P < 0.05). The adverse reaction rate was 10.9% and 9.1% (P > 0.05). The proportion of persons with poor prognosis and no improvement of cardiac function in patients with highly expressed CRP before treatment was higher as against patients with low expression of CRP (P < 0.05). Highly expressed CRP is an independent risk factor for poor prognosis.Conclusion: Vericiguat is safe and effective in improving cardiac function in HHF patients.","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"High Blood Pressure & Cardiovascular Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40292-024-00664-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Hypertensive heart failure (HHF) has a high incidence and poor prognosis.

Aim: This article evaluated the efficacy and safety of Vericiguat in HHF and analyzed the relationship between C-reactive protein (CRP) levels and patient prognosis.

Methods: 110 HHF patients were divided into Placebo and Vericiguat groups. Cardiac function was assessed by echocardiography and 6-minute walk test (6MWT). Blood samples were collected to detect the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI), endothelin (ET-1), nitric oxide (NO), and CRP.

Results: Left ventricular end systolic diameter (LVESD) and left ventricular end diastolic dimension (LVEDD) were reduced, the left ventricular ejection fraction (LVEF) and 6MWT were increased, and the serum levels of NT-proBNP, cTnI, ET-1, NO, and CRP were decreased in Vericiguat group as against Placebo group; The total effective rate was 76.4% in Placebo group and 92.7% in Vericiguat group (P < 0.05). The adverse reaction rate was 10.9% and 9.1% (P > 0.05). The proportion of persons with poor prognosis and no improvement of cardiac function in patients with highly expressed CRP before treatment was higher as against patients with low expression of CRP (P < 0.05). Highly expressed CRP is an independent risk factor for poor prognosis.

Conclusion: Vericiguat is safe and effective in improving cardiac function in HHF patients.

查看原文本刊更多论文

韦立克对高血压性心力衰竭患者 C 反应蛋白水平和预后的影响

简介：高血压性心力衰竭（HHF）发病率高、预后差：目的：本文评估了维力青治疗高血压性心力衰竭的有效性和安全性，并分析了C反应蛋白（CRP）水平与患者预后之间的关系。方法：110名高血压性心力衰竭患者被分为安慰剂组和维力青组。通过超声心动图和 6 分钟步行测试（6MWT）评估心脏功能。采集血样检测 N 端前脑钠肽 (NT-proBNP)、心肌肌钙蛋白 I (cTnI)、内皮素 (ET-1)、一氧化氮 (NO) 和 CRP 的水平：结果：与安慰剂组相比，韦立奎特组的左心室收缩末期直径（LVESD）和左心室舒张末期尺寸（LVEDD）减小，左心室射血分数（LVEF）和6MWT增加，血清中NT-proBNP、cTnI、ET-1、NO和CRP水平降低；安慰剂组的总有效率为76.4%，韦立奎特组的总有效率为92.7%（P 0.05）。治疗前 CRP 表达高的患者预后不良和心功能无改善的比例高于 CRP 表达低的患者（P 结论：CRP 表达高的患者预后不良和心功能无改善的比例高于 CRP 表达低的患者：韦立克对改善 HHF 患者的心功能安全有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

High Blood Pressure & Cardiovascular Prevention PERIPHERAL VASCULAR DISEASE-

CiteScore

5.70

自引率

3.30%

发文量

期刊介绍： High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes: Invited ''State of the Art'' reviews. Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.''Pros and Cons'' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.

文献相关原料

公司名称	产品信息	采购帮参考价格